Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | CTSV | O60911 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.49 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597702 | 0.91 | MEN1 (0.63) | MEN1KMT2AMRGPRX4MAOBNR4A2 | |
| SCHEMBL10659926 | 0.89 | MEN1 (0.51) | MEN1KMT2AMRGPRX4MCL1MAOB | |
| SCHEMBL7921994 | 0.87 | KMT2A (0.58) | MEN1KMT2AMRGPRX4MCL1MAOB | |
| SCHEMBL13965398 | 0.85 | MEN1 (0.56) | MEN1KMT2AMRGPRX4MCL1MAOB | |
| SCHEMBL1842000 | 0.85 | MEN1 (0.56) | MEN1KMT2AMRGPRX4MCL1MAOB | |
| SCHEMBL27489408 | 0.84 | MEN1 (0.63) | MEN1KMT2AMRGPRX4MCL1MAOB | |
| SCHEMBL10657327 | 0.84 | MEN1 (0.55) | MEN1KMT2AMRGPRX4MCL1MAOB | |
| SCHEMBL22490923 | 0.83 | MEN1 (0.54) | MEN1KMT2AMRGPRX4MAOBNR4A2 | |
| SCHEMBL1022035 | 0.82 | MAOB (0.64) | MEN1KMT2AMRGPRX4MCL1MAOB | |
| Benzene SCHEMBL28056879 | 0.82 | MAOB (0.64) | MEN1KMT2AMRGPRX4MCL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| US-4745116-A | INHIBITORS OF SERINE PROTEASE | SYNTEX (U.S.A.) INC. (US) | 1988-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | MEN1 1035/4885KMT2A 3063/4885MRGPRX4 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.